Orexigen’s New Diet Pill, Contrave, Nears FDA Approval

Contrave, a new diet pill from the pharmaceutical company Orexigen, won a U.S. panel recommendation that brings it one step closer to winning FDA approval, which will be announced after the final vote on January 31. Despite associated cardiovascular risks, the drug is expected to win approval, which would make it the first new diet pill to come on the market in the last decade.

Contrave contains two previously approved drugs: Bupropion, an antidepressant, and naltrexone, a drug used to help kick addictions. If approved, it’s expected to bring in huge profits, with sale estimates reaching $16 billion in 2016.

via Bloomberg

Share This Post: